Contact lens compositions
In one embodiment, the invention provides a contact lens comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
1 . A contact lens comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
2 . The lens of claim 1 , wherein said phospholipid moiety is phosphatidylethanolamine.
3 . The lens of claim 2 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
4 . The lens of claim 3 , wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine.
5 . The lens of claim 1 , wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is polygeline.
6 . The lens of claim 1 , wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is a polypyranose.
7 . The lens of claim 6 , wherein said polypyranose is carboxymethylcellulose.
8 . The lens of claim 6 , wherein said polypyranose is alginate.
9 . The lens of claim 6 , wherein said polypyranose is hydroxyethyl starch.
10 . The lens of claim 6 , wherein said polypyranose is a glycosaminoglycan.
11 . The lens of claim 10 , wherein said glycosaminoglycan is hyaluronic acid.
12 . The lens of claim 10 , wherein said glycosaminoglycan is heparin.
13 . The lens of claim 10 , wherein said glycosaminoglycan is chondroitin sulfate.
14 . The lens of claim 1 , wherein said lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer is coated on at least a portion of a surface of said contact lens.
15 . The lens of claim 1 , wherein said lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer is embedded in at least a portion of said contact lens.
16 . The lens of claim 1 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (A):
wherein
L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, phosphate, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and
n is a number from 2 to 1000;
wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
17 . The lens of claim 16 , L is phosphatidyl, Z is ethanolamine, Y is nothing, and X is carboxymethylcellulose or a glycosaminoglycan.
18 . The lens of claim 16 , wherein the phosphatidylethanolamine moiety is dipalmitoyl or dimyristoyl phosphatidylethanolamine.
19 . The lens of claim 16 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (I):
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; and
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer, and wherein X is a glycosaminoglycan; and
n is a number from 1 to 1000;
wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond.
20 . The lens of claim 16 , n is a number from 2 to 100.
21 . The lens of claim 16 , wherein X is hyaluronic acid, heparin or chondroitin sulfate.
22 . A method of treating an ocular surface disease in a subject, the method comprising applying a lens of claim 1 to the eye of a subject.
23 . The method of claim 22 , wherein said disease is dry eye or Keratoconus.